menu
    • menu
    [{"orgOrder":0,"company":"BioAge Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Azelaprag","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Labs \/ Eli Lilly"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series D Financing","leadProduct":"Azelaprag","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0.17000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"BioAge Labs \/ Sofinnova Investments","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Labs \/ Sofinnova Investments"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Azelaprag","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioAge Labs \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Azelaprag

    Menu

    Azelaprag

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioAge Labs

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            BioAge Labs

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaprag,Tirzepatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioAge Doses First Patient in Phase 2 Trial of Azelaprag for Obesity with Tirzepatide

                            Details : BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound (tirzepatide) and other incretins for the treatment of obesity.

                            Brand Name : BGE-105

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 29, 2024

                            Lead Product(s) : Azelaprag,Tirzepatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioAge Labs

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            BioAge Labs

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaprag,Tirzepatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Sofinnova Investments

                            Deal Size : $170.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            BioAge Raises $170 Million Series D for Obesity and Metabolic Disease Therapy

                            Details : Funding will support Phase II development of BioAge’s BGE-105 (azelaprag), an oral apelin receptor agonist in combination with Lilly’s Zepbound for obesity treatment.

                            Brand Name : BGE-105

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 13, 2024

                            Lead Product(s) : Azelaprag,Tirzepatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Sofinnova Investments

                            Deal Size : $170.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BioAge Labs

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            BioAge Labs

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelaprag,Tirzepatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-A...

                            Details : As part of the collaboration, Lilly will supply tirzepatide and Chorus will provide clinical trial design and execution expertise. BioAge retains worldwide exclusive rights to develop and commercialize BGE-105 (azelaprag) for all indications.

                            Brand Name : BGE-105

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 26, 2023

                            Lead Product(s) : Azelaprag,Tirzepatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth